Biotech Business - January 14, 2025
FDA accepts BioArctic’s partner Eisai’s BLA for subcutaneous maintenance dosing of Leqembi in the US
The U.S. Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosing.
Biotech Business - January 13, 2025
Elicera’s drug candidate receives Orphan Drug Designation in the US
Elicera Therapeutics' drug candidate ELC-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic neuroendocrine tumors.
Agreement - December 19, 2024
BioArctic enters global license agreement with Bristol Myers Squibb
BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology.
Acquisition - December 18, 2024
Ultimovacs combines its business with Zelluna Immunotherapy
Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.
Biotech Business - December 17, 2024
Orexo and Abera collaborate
Orexo has entered into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology.
Biotech Business - December 16, 2024
Medivir obtains IND approval for fostrox
Medivir has announced the approval of the US Investigational New Drug application (IND) for evaluating fostrox + Lenvima vs Lenvima alone in a phase 2b study in 2nd line advanced HCC.
